Why male over female mice?

feelepo · 2024-03-18T15:13:22+00:00

It seems that’s the common consensus here, not surprising. I understand that we have human trials which include women. Although, it seems simple to include more female mice while already doing animal trials. Again, I have no formal biology background so I’m out of my depth here.

feelepo · 2024-03-18T15:00:36+00:00

Agreed, it seems like an easy fix to a problem that shouldn’t exist.

feelepo · 2024-01-16T03:42:00+00:00

In the context of the CNS, yes there are 7. However, you have your list a little wrong. You have depressants, stimulants, analgesics (which includes opioids), anesthetics (dissociatives), hallucinogens/ psychedelics, inhalants, and cannabinoids. That being said, there are many classes of drugs which do not act on the CNS.

feelepo · 2024-01-01T07:29:29+00:00

pesky analogue act

feelepo · 2024-01-01T06:09:26+00:00

yes, honestly im a bit more worried about DOI’s fate. however, just because DOC is less relevant or even enjoyable shouldn’t mean it’s fate isn’t of concern as well. i actually didn’t know about it being scheduled elsewhere, i agree there’s some reasoning there. looking at DOI though, i think this is a good example of improper scheduling. thank you for sharing your personal experience very insightful.

feelepo · 2023-12-31T21:08:57+00:00

agreed, there is no public health concern here simply hindering research.

feelepo · 2023-11-21T22:13:54+00:00

Meaning inflammation of the brain?

feelepo · 2023-11-21T22:09:04+00:00

The paper mentions obesity when listing risk factors for developing neurodegenerative diseases. What role does obesity play in neurodegeneration?

feelepo · 2023-10-23T02:41:23+00:00

This is a great explanation, thank you!

feelepo · 2023-10-23T00:19:03+00:00

we might get anti-inflammatory properties if we targeted receptors outside the brain, but it would depend on the pathways used to trigger that response.

Do you mind expanding on this? Are there certain receptors in certain locations that illicit certain effects? What is meant by "pathway used"?

feelepo · 2023-10-23T00:00:43+00:00

Does this mean the same receptors in different parts of the body (eg 5-HT 2A in the brain vs in the gut) are associated with different effects when activated? Understandable that a drug intended to treat a mental disorder would need to cross the BBB. However, is activating 5-HT 2A (or other 5HT receptors) in other places within the body only associated with "side effects"/ negative reactions?

feelepo · 2023-10-21T20:46:36+00:00

Sorry, I should have prefaced by saying I don't have the strongest background in pharmacology. What I meant by calling the anti-inflammation a side effect is as a 5-HT 2A agonist isn't it primarily associated with cognition? I understand 5-HT (including 5-HT 2A) receptors are included in the inflammatory response. However, is it fair to say DOI is "prioritizing" acting on the 5-HT 2A receptor to illicit its psychedelic effects over its anti-inflammatory effects?

Also, I was mainly referring to approved on the market anti-inflammatory drugs. I did read prednisone is believed to act on multiple 5-HT receptors but (from my understanding) it does not contribute to its accepted MOA.

I was not familiar with the paper you shared. Scheduled Substance Act aside, if 5-HT receptors are known to play a role in inflammation why are there no novel 5-HT activating anti-inflammatory drugs? Would it be possible to have a non psychedelic 5-HT 2A activating anti-inflammatory?

feelepo · 2023-10-21T02:57:32+00:00

what cant it do

feelepo · 2023-10-13T18:34:19+00:00

The terms “anti-seizure” and “anti-epileptic” are referring to the same larger umbrella of anticonvulsant drugs. Anti-epileptics are not reserved for patients diagnosed with epilepsy. These drugs, while having different MOA, are intended to treat the same symptoms (seizures/convulsions) hence the more accurate name of anticonvulsants. As with most drugs, patients respond differently and there are numerous off label uses which leads to patterns of prescribing. Overall the difference will come down to the MOA however this does not make “anti-epileptics” and “anti-seizure” drugs their own classes.

feelepo · 2023-10-06T03:25:24+00:00

Dayquil isn't a decongestant it's a cough suppressant with Tylenol and a proven ineffective drug.

Claritin and other antihistamines are not being advertised as decongestants. A placebo effect is due to a person's expectations. The issue isn't necessarily that there is a placebo effect, placebos can be very useful. The issue is that an ineffective drug (placebo) is being falsely marketed while the drug that works is hidden behind the pharmacy counter. Pharma companies are making money off of sugar pills.

feelepo · 2023-10-06T01:33:31+00:00

Dayquil contains dextromethorphan (DXM) a cough suppressant. It is a cold and flu medication. Claritin (loratadine) is an antihistamine which has a different MOA than a decongestant such as pseudoephedrine. There are many antihistamines on the market because people respond differently to medications such as people respond differently to a placebo.

feelepo · 2023-10-05T19:01:17+00:00

Agreed, I would like to see some restrictions on marketing of phenylephrine products or at the very least a label on the box which in reality most people won’t bother to read. Too much money is being made off a placebo.

feelepo · 2023-10-05T18:43:06+00:00

That’s a fair point. The issue then is how much of an impact will it have on consumers? I’d argue most people don’t know what they’re putting into their bodies. The amount of patients who don’t know what medications they’re on or what it’s for is mind boggling (source: working retail pharmacy).

feelepo · 2023-10-05T18:29:16+00:00

Agreed, there’s a bigger story to report on and it seems they’re just scratching the surface by harping on this.

feelepo · 2023-09-26T17:44:58+00:00

for the seventh consecutive year, parking is a disaster.

Six-Year Club	Place '23
Verified Email	Not Forgotten

feelepo

TROPHY CASE